Plus Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Plus Therapeutics
PSTV Stock  USD 0.56  0.05  9.80%   
Plus Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Plus Therapeutics' valuation are provided below:
Gross Profit
-2.4 M
Market Capitalization
77.1 M
Enterprise Value Revenue
18.192
Revenue
5.3 M
Earnings Share
(0.96)
There are over one hundred nineteen available trending fundamental ratios for Plus Therapeutics, which can be analyzed over time and compared to other ratios. All traders should should check out Plus Therapeutics' recent fundamental trends against the trends from 2010 to 2026 to make sure the company is sustainable. Market Cap is likely to drop to about 4.6 M in 2026. Enterprise Value is likely to drop to about 1.2 M in 2026

Plus Therapeutics Total Revenue

5.87 Million

Check Plus Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Plus Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 2.3 M, Selling General Administrative of 10.1 M or Selling And Marketing Expenses of 637 K, as well as many indicators such as Price To Sales Ratio of 1.12, Dividend Yield of 0.0 or Days Sales Outstanding of 42.94. Plus financial statements analysis is a perfect complement when working with Plus Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Plus Stock
Check out the analysis of Plus Therapeutics Correlation against competitors.
For more information on how to buy Plus Stock please use our How to Invest in Plus Therapeutics guide.

Plus Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets5.7 M6 M24.4 M
Slightly volatile
Short and Long Term Debt Total3.7 M3.9 M12.9 M
Slightly volatile
Cash83 K87.4 K12.1 M
Slightly volatile
Non Current Assets Total1.2 M1.2 M7.8 M
Slightly volatile
Other Assets10.3 K10.8 K1.7 M
Slightly volatile
Cash And Short Term Investments3.1 M3.2 M12.7 M
Slightly volatile
Common Stock Shares Outstanding9.3 M8.9 M1.9 M
Slightly volatile
Liabilities And Stockholders Equity5.7 M6 M24.4 M
Slightly volatile
Non Current Liabilities Total26.5 K27.9 K9.2 M
Slightly volatile
Other Stockholder Equity585.1 M557.2 M388.3 M
Slightly volatile
Total Liabilities24.5 M17.9 M22.3 M
Slightly volatile
Total Current Assets4.5 M4.7 M16.6 M
Slightly volatile
Total Current Liabilities13.3 M14 M12.3 M
Pretty Stable
Property Plant And Equipment Net445.5 K468.9 K1.7 M
Slightly volatile
Non Currrent Assets Other13.1 K13.8 K1.7 M
Slightly volatile
Net Receivables1 M513.9 K1.2 M
Slightly volatile
Other Current Assets1.3 M1.2 M1.5 M
Pretty Stable
Short Term Debt5.4 M3.8 M6.8 M
Pretty Stable
Common Stock5.1 K5.4 K3.4 M
Slightly volatile
Current Deferred Revenue120.6 K126.9 K260.6 M
Slightly volatile
Common Stock Total Equity7.6 K8.1 K38.4 K
Slightly volatile
Property Plant And Equipment Gross2.1 M3.3 M2.4 M
Pretty Stable
Good Will318.1 K334.8 K2.1 M
Slightly volatile
Intangible Assets401 K422.1 K3.7 M
Slightly volatile
Capital Surpluse424.5 M502 M392.4 M
Slightly volatile
Property Plant Equipment2 M1.8 M1.7 M
Slightly volatile
Other Liabilities1.4 M1.9 M1.1 M
Slightly volatile
Capital Stock13.7 K6.9 K13.4 K
Pretty Stable

Plus Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Expense2.3 M3.4 M2.3 M
Pretty Stable
Selling General Administrative10.1 M11.4 M9.6 M
Pretty Stable
Selling And Marketing Expenses637 K670.5 K3.2 M
Slightly volatile
Other Operating Expenses28.1 M23.6 M24.6 M
Slightly volatile
Research Development11.6 M12.2 M10.6 M
Pretty Stable
Total Operating Expenses24.8 M22.6 M21.8 M
Slightly volatile
Cost Of Revenue930.8 K979.8 K2.6 M
Very volatile
Depreciation And Amortization949.8 K766.8 K979.9 K
Pretty Stable
Interest Income352.7 K245.7 K1.3 M
Slightly volatile
Reconciled Depreciation778.2 K650.7 K1.4 M
Slightly volatile

Plus Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow13.7 M9.8 M16.6 M
Slightly volatile
End Period Cash Flow83 K87.4 K12.3 M
Slightly volatile
Depreciation971.6 K650.7 K959.8 K
Pretty Stable
Stock Based Compensation470.2 K495 K68.2 M
Slightly volatile
Issuance Of Capital Stock8.6 M6.5 M9.4 M
Very volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.121.18220.2 K
Slightly volatile
Days Sales Outstanding42.9432.2153.4992
Slightly volatile
Stock Based Compensation To Revenue0.08070.0850.5153
Pretty Stable
Capex To Depreciation0.220.230.8868
Slightly volatile
Inventory Turnover12.9612.346.3111
Slightly volatile
Days Of Inventory On Hand29.0930.62242
Slightly volatile
Payables Turnover0.09820.12.5251
Slightly volatile
Sales General And Administrative To Revenue1.691.542.5607
Pretty Stable
Research And Ddevelopement To Revenue2.851.637.0762
Slightly volatile
Capex To Revenue0.02140.02260.565
Pretty Stable
Cash Per Share0.590.627.7 K
Slightly volatile
Days Payables Outstanding3.8 K3.7 K1.9 K
Slightly volatile
Income Quality1.130.940.9113
Pretty Stable
Intangibles To Total Assets0.190.150.1571
Slightly volatile
Current Ratio0.370.393.4233
Slightly volatile
Receivables Turnover13.5311.739.2372
Slightly volatile
Capex Per Share0.0240.0253407
Slightly volatile
Revenue Per Share0.961.012.6 K
Slightly volatile
Interest Debt Per Share1.171.235.3 K
Slightly volatile
Debt To Assets0.260.460.4667
Slightly volatile
Operating Cycle30.632.21280
Slightly volatile
Days Of Payables Outstanding3.8 K3.7 K1.9 K
Slightly volatile
Ebt Per Ebit0.780.791.0029
Slightly volatile
Long Term Debt To Capitalization0.350.330.4818
Slightly volatile
Quick Ratio0.370.393.2063
Slightly volatile
Net Income Per E B T3.132.982.2524
Slightly volatile
Cash Ratio0.00530.00561.4343
Slightly volatile
Days Of Inventory Outstanding29.0930.62242
Slightly volatile
Days Of Sales Outstanding42.9432.2153.4992
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.281.171.1038
Pretty Stable
Fixed Asset Turnover10.5610.065.292
Very volatile
Debt Ratio0.260.460.4667
Slightly volatile
Price Sales Ratio1.121.18220.2 K
Slightly volatile
Asset Turnover0.830.790.3251
Slightly volatile

Plus Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap4.6 M6.9 M4.1 M
Slightly volatile
Enterprise Value1.2 M1.3 M4.1 M
Slightly volatile

Plus Fundamental Market Drivers

Plus Upcoming Events

22nd of February 2024
Upcoming Quarterly Report
View
18th of April 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
22nd of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Plus Therapeutics Financial Statements

Plus Therapeutics investors use historical fundamental indicators, such as Plus Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Plus Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue126.9 K120.6 K
Total Revenue5.2 M5.9 M
Cost Of Revenue979.8 K930.8 K
Stock Based Compensation To Revenue 0.09  0.08 
Sales General And Administrative To Revenue 1.54  1.69 
Research And Ddevelopement To Revenue 1.63  2.85 
Capex To Revenue 0.02  0.02 
Revenue Per Share 1.01  0.96 
Ebit Per Revenue(2.90)(3.05)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Plus Stock Analysis

When running Plus Therapeutics' price analysis, check to measure Plus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Plus Therapeutics is operating at the current time. Most of Plus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Plus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Plus Therapeutics' price. Additionally, you may evaluate how the addition of Plus Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY